GTN administration induces an increase in nNOS that is simultaneous with a hyperalgesic condition and neuronal activation in brain areas involved in migraine pain [38, 39], thus suggesting that NOS inhibition may be a potential therapeutic target for migraine. This evidence concerns the gene NOS1 and migraine disorder.